MedPath

CYT-107

Generic Name
CYT-107

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

Phase 2
Terminated
Conditions
COVID-19
Lymphocytopenia
Interventions
Drug: Placebo
First Posted Date
2020-06-22
Last Posted Date
2022-04-08
Lead Sponsor
Revimmune
Target Recruit Count
26
Registration Number
NCT04442178
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Florida College of Medicine, Gainesville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Missouri Baptist Medical Center, Saint Louis, Missouri, United States

๐Ÿ‡บ๐Ÿ‡ธ

Rutgers Health, New Brunswick, New Jersey, United States

and more 2 locations

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

Phase 2
Terminated
Conditions
Lymphocytopenia
COVID-19
Interventions
Drug: Placebo
First Posted Date
2020-06-11
Last Posted Date
2024-04-11
Lead Sponsor
Revimmune
Target Recruit Count
10
Registration Number
NCT04426201
Locations
๐Ÿ‡บ๐Ÿ‡ธ

MD Anderson cancer center, Houston, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial sloan kettering, New York, New York, United States

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Phase 1
Withdrawn
Conditions
Umbilical Cord Blood Transplant
Interventions
First Posted Date
2018-07-26
Last Posted Date
2019-01-10
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT03600896

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders

Phase 2
Terminated
Conditions
HIV
Interventions
First Posted Date
2010-11-16
Last Posted Date
2013-07-25
Lead Sponsor
Cytheris SA
Target Recruit Count
92
Registration Number
NCT01241643
Locations
๐Ÿ‡ฟ๐Ÿ‡ฆ

Helen Joseph Hospital-Themba Lethu Clinic, Johannesbourg, South Africa

๐Ÿ‡จ๐Ÿ‡ญ

University of Zurich, Zurich, Switzerland

๐Ÿ‡ฎ๐Ÿ‡น

San Raffaele Scientific Institute, Milano, Italy

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Phase 1
Terminated
Conditions
Idiopathic CD4+ T-Lymphocytopenia
Interventions
First Posted Date
2009-02-09
Last Posted Date
2015-10-15
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
21
Registration Number
NCT00839436
Locations
๐Ÿ‡บ๐Ÿ‡ธ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety Study of IL-7 in HIV-infected Patients (Inspire)

Phase 1
Completed
Conditions
HIV Infections
Lymphopenia
Interventions
First Posted Date
2007-05-23
Last Posted Date
2012-10-18
Lead Sponsor
Cytheris SA
Target Recruit Count
30
Registration Number
NCT00477321
Locations
๐Ÿ‡ฎ๐Ÿ‡น

San Raffaele Scientific Institute, Milano, Italy

๐Ÿ‡ซ๐Ÿ‡ท

Hopital Henri Mendor-Service d'Immunologie Clinique, Creteil, France

๐Ÿ‡ซ๐Ÿ‡ท

Hopital Saint Louis, Paris, France

and more 5 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath